Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report Just Published by Credence Research Inc.

According to the latest market report published by Credence Research, Inc. “Amyotrophic lateral sclerosis (ALS) Treatment  Market was valued at US$ 51.04 Mn in 2016, and is expected to reach US$ 306.6 Mn by 2025, expanding at a CAGR of  21.1% from 2017 to 2025.
The purpose of the report is to illustrate the state of the market of Amyotrophic Lateral Sclerosis (ALS) Treatment, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2025.
Market Insights:
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes death of nerve cells that control voluntary muscles. According to National Organization for Rare Disorders (NORD), ALS is a is a rare disorder that affects approximately 30,000 people in the United States, approximately 5,000 new cases are diagnosed each year in the United States. Currently, there is no cure for ALS however, treatments are available to control symptoms and to prevent complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS it includes Riluzole and Edaravone, other medications are prescribe to control ALS symptoms. It is studied that in the base year 2016, Riluzole (Rilutek) was major revenue generating segment because riluzole was the only approved drug for a treatment of ALS, however patent expiry of Rilutek in 2013 has been negatively impacting the ALS treatment market growth. 
Download Free Request Checkout: https://www.credenceresearch.com/checkout/58605
Leading Players:
players. However, the market is currently dominated by few players such as AB Science, Avicena Group, Biogen, BrainStorm Therapeutics, Covis Pharmaceutical Inc., Cytokinetics Inc., Eisai Co. Ltd., GlaxoSmithKline plc., Ionis Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corp., Neuralstem Inc., Neuraltus Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Pharnext SAS, Q-Therapeutics Inc. and other.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Amyotrophic Lateral Sclerosis (ALS) Treatment buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
Browse here for full report with Toc: https://www.credenceresearch.com/report/amyotrophic-lateral-sclerosis-als-treatment-market
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Amyotrophic Lateral Sclerosis (ALS) Treatment contains:
Analysis and forecast of Amyotrophic Lateral Sclerosis (ALS) Treatment market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Amyotrophic Lateral Sclerosis (ALS) Treatment market;
Assessment and forecast of Amyotrophic Lateral Sclerosis (ALS) Treatment market development;
Financial and business profiles of the leading companies in the Amyotrophic Lateral Sclerosis (ALS) Treatment industry.
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58605
Scope
- Up to date working Amyotrophic Lateral Sclerosis (ALS) Treatment data by major regions in the world, the forecast of planned capacity additions by 2026
- The annual breakdown of capital expenditure spending on proposed Amyotrophic Lateral Sclerosis (ALS) Treatment for the period 2018 to 2026
- Planned Amyotrophic Lateral Sclerosis (ALS) Treatment additions and capital expenditure spending by key countries and companies across the world
- Planned capital expenditure spending on new Amyotrophic Lateral Sclerosis (ALS) Treatment projects by region, key countries, and companies
- Details of major planned Amyotrophic Lateral Sclerosis (ALS) Treatment projects in the world up to 2026
Our Blogs: http://www.technicaltop.com/2017/08/04/global-amyotrophic-lateral-sclerosis-als-treatment-market-size-share-growth-outlook-opportunities-and-forecast-2017-to-2025/
http://www.mobilecomputingtoday.co.uk/6166/amyotrophic-lateral-sclerosis-als-treatment-market-expected-reach-306-6-2025-credence-research/